[SCHEDULE 13G/A] Roivant Sciences Ltd. SEC Filing

Rhea-AI Filing Summary

QVT Financial LP reported beneficial ownership of 29,381,635 common shares of Roivant Sciences Ltd., representing 4.30% of the outstanding class. The filing is a Schedule 13G (Amendment No. 5) covering common shares (CUSIP G76279101) with the relevant event date noted as 06/30/2025. QVT reports sole voting and dispositive power over all shares disclosed. The statement is a passive ownership disclosure rather than an active solicitation filing and indicates transparency about a sub-5% stake rather than a controlling position.

Insights

Securities Analyst

TL;DR: QVT holds a disclosed passive 4.30% stake in Roivant, reporting sole voting and dispositive power over 29.38M shares.

The filing documents a non-controlling, beneficial position below the 5% threshold that would typically require further regulatory treatment as a potential activist or control person. QVT's sole voting and dispositive power is notable for transparency but does not by itself indicate intent to influence management. For investors, this is a routine disclosure showing an institutional holder with meaningful but not control-level ownership.

Corporate Governance Expert

TL;DR: This is a routine Schedule 13G amendment showing passive ownership; it does not signal a change in governance control.

The amendment formalizes current holdings and confirms sole voting/dispositive authority for QVT over the reported shares. Because the stake is 4.30%, it falls below thresholds that typically trigger mandatory activist disclosure or control presumptions. The filing supports market transparency without indicating material governance action.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

Roivant Sciences Ltd.

(Name of Issuer)

Common shares, par value $0.0000000341740141 per share

(Title of Class of Securities)

G76279101

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G76279101

1

Names of Reporting Persons

QVT Financial LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 29,381,635.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 29,381,635.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

29,381,635.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.30 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Roivant Sciences Ltd.
(b)	Address of issuer's principal executive offices: 7th Floor, 50 Broadway, London SW1H 0DB, United Kingdom
Item 2.
(a)	Name of person filing: QVT Financial LP
(b)	Address or principal business office or, if none, residence: 888 Seventh Avenue, 43rd Floor, New York, NY 10106
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common shares, par value $0.0000000341740141 per share
(e)	CUSIP No.: G76279101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 29,381,635
(b)	Percent of class: 4.30 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 29,381,635
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 29,381,635
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

QVT Financial LP

Signature:	/s/ Meg Eisner
Name/Title:	Authorized Signatory
Date:	08/14/2025

FAQ

How many Roivant (ROIV) shares does QVT Financial LP report owning?

QVT Financial LP reports beneficial ownership of 29,381,635 shares of Roivant (4.30% of the class).

Does QVT have voting or dispositive power over the reported ROIV shares?

Yes. The filing states QVT has sole voting power and sole dispositive power over all 29,381,635 shares.

What form was filed for this Roivant disclosure?

The disclosure was made on a Schedule 13G (Amendment No. 5) for Roivant Sciences Ltd., common shares (CUSIP G76279101).

What date is associated with the event requiring this filing?

The filing lists the date of the event requiring the statement as 06/30/2025.

When was the Schedule 13G signed?

The signature block shows the filing was signed by an authorized signatory, /s/ Meg Eisner, dated 08/14/2025.